Patents by Inventor Sarah Lewis

Sarah Lewis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240156238
    Abstract: A carriable device can include a body that includes a first side, a second, opposing side, a first strap mount on the first side, and a second strap mount socket on the second side; and a strap that includes an end attached to the body, an opposing end, and a coupling attached to the opposing end, where the coupling is connectable to the first strap mount and wherein the coupling is connectable to the second strap mount.
    Type: Application
    Filed: November 15, 2022
    Publication date: May 16, 2024
    Inventors: Sarah Lewis, Julia Young, Ali Ent, Thomas Perelli
  • Patent number: 9751876
    Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: September 5, 2017
    Assignee: Novartis AG
    Inventors: Ian Bruce, Sylvie Chamoin, Stephen Paul Collingwood, Pascal Furet, Vikki Furminger, Diana Janus, Sarah Lewis, Jon Christopher Loren, Valentina Molteni, Alex Michael Saunders, Duncan Shaw, Lilya Sviridenko, Christopher Thomson, Ryan West, Vince Yeh
  • Patent number: 9512151
    Abstract: A compound of Formula (II) and (III), or a mixture of any two or more thereof; wherein M is Ti or Zr; R3 at each occurrence is H, F, Cl, Br, I, CN, OR4, NR5R6, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl; R4 is H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl; R5 and R6 are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclylalkyl, or R5 and R6 may join to form a heterocyclic ring containing the N to which they are attached; and n?=0-4. Such compounds form optically transparent and/or clear films or particles or may be used to prepare such materials.
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: December 6, 2016
    Assignee: AUTERRA, INC.
    Inventors: Kyle E. Litz, Partha Dutta, Sarah Lewis, Mark Rossetti, James Pawlson, Timothy Ullman, Giyana Amaratunga, Jennifer L. Vreeland, Tracey M. Jordan
  • Patent number: 9073921
    Abstract: The present invention provides novel solid forms of pharmaceutically active agents and therapeutic uses thereof. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: July 7, 2015
    Assignee: Novartis AG
    Inventors: Ian Bruce, Sylvie Chamoin, Stephen Paul Collingwood, Pascal Furet, Vikki Furminger, Sarah Lewis, Jon Christopher Loren, Lin Lv, Valentina Molten, Alex Michael Saunders, Duncan Shaw, Roy Maxwell Turner, Vince Yeh
  • Publication number: 20150025059
    Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 22, 2015
    Applicant: Novartis AG
    Inventors: Ian Bruce, Sylvie Chamoin, Stephen Paul Collingswood, Pascal Furet, Vikki Furminger, Diana Janus, Sarah Lewis, Jon Christopher Loren, Valentina Molteni, Alex Michael Saunders, Duncan Shaw, Lilya Sviridenko, Christopher Thomson, Ryan West, Vince Yeh
  • Patent number: 8883819
    Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: November 11, 2014
    Assignees: IRM LLC, Novartis AG
    Inventors: Ian Bruce, Sylvie Chamoin, Stephen Paul Collingwood, Pascal Furet, Vikki Furminger, Diana Janus, Sarah Lewis, Jon Christopher Loren, Valentia Molteni, Alex Michael Saunders, Duncan Shaw, Lilya Sviridenko, Christopher Thomson, Ryan West, Vince Yeh
  • Publication number: 20140249177
    Abstract: The present invention provides novel solid forms of pharmaceutically active agents and therapeutic uses thereof. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: February 21, 2014
    Publication date: September 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Ian BRUCE, Sylvie CHAMOIN, Stephen Paul COLLINGWOOD, Pascal FURET, Vikki FURMINGER, Sarah LEWIS, Jon Christopher LOREN, Lin LV, Valentina MOLTEN, Alex Michael SAUNDERS, Duncan SHAW, Roy Maxwell TURNER, Vince YEH
  • Publication number: 20140206682
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of PDGFR (PDGFR?, PDGFR?) kinases or c-kit and PDGFR (PDGFR?, PDGFR?) kinases.
    Type: Application
    Filed: August 31, 2012
    Publication date: July 24, 2014
    Applicants: NOVARTIS PHARMACEUTICALS UK LIMITED, IRM LLC
    Inventors: Fang Liang, Michael Gibney, Vince Yeh, Xiaolin Li, Valentina Molteni, Duncan Shaw, Ashley Mitchell Berman, Sarah Lewis, Jon Loren, Vikki Furminger
  • Publication number: 20140086879
    Abstract: Disclosed herein is an isolated Muscodor albus strain producing volatile organic compounds such as aristolene, 3-octanone and/or acetic acid ester, as well as cultures of said strain and compositions, metabolites and volatiles derived from said strain or culture as well as methods of obtaining said compositions, metabolites and volatiles and their methods of use for controlling pests. Also disclosed are artificial compositions having the same components and uses as the volatiles derived from the strain. A method for capturing and sampling the volatiles is also disclosed.
    Type: Application
    Filed: September 23, 2013
    Publication date: March 27, 2014
    Applicant: Marrone Bio Innovations, Inc.
    Inventors: Gary Strobel, Vu Phong Bui, Hai Su, Phyllis Himmel, Pamela Marrone, Lijuan Xing, Sarah Lewis
  • Publication number: 20130237519
    Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
    Type: Application
    Filed: August 30, 2012
    Publication date: September 12, 2013
    Inventors: Ian Bruce, Sylvie Chamoin, Stephen Paul Collingwood, Pascal Furet, Vikki Furminger, Diana Janus, Sarah Lewis, Jon Christopher Loren, Valentina Molteni, Alex Michael Saunders, Duncan Shaw, Lilya Sviridenko, Christopher Thomson, Ryan West, Vince Yeh
  • Patent number: 8367662
    Abstract: Compounds of formula I: in free or salt or solvate form, where R1, R2, R3 and R20 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: February 5, 2013
    Assignee: Novartis AG
    Inventors: Duncan Shaw, Catherine Leblanc, Dimitrios Lizos, Cathy Ritchie, Vikki Furminger, Sarah Lewis, Benoit Hornsperger, Nikolaus Johannes Stiefl, Sven Weiler
  • Publication number: 20110119988
    Abstract: A compound of Formula (II) and (III), or a mixture of any two or more thereof; wherein M is Ti or Zr; R3 at each occurrence is H, F, Cl, Br, I, CN, OR4, NR5R6, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl; R4 is H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl; R5 and R6 are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclylalkyl, or R5 and R6 may join to form a heterocyclic ring containing the N to which they are attached; and n?=0-4. Such compounds form optically transparent and/or clear films or particles or may be used to prepare such materials.
    Type: Application
    Filed: May 2, 2008
    Publication date: May 26, 2011
    Inventors: Kyle E. Litz, Partha Dutta, Sarah Lewis, Mark Rossetti, James Pawlson, Timothy Ullman, Giyana Amaratunga, Jennifer M. Vreeland, Tracey M. Jordan
  • Publication number: 20100210641
    Abstract: Compounds of formula I: in free or salt or solvate form, where R1, R2, R3 and R20 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis.
    Type: Application
    Filed: October 15, 2008
    Publication date: August 19, 2010
    Inventors: Duncan Shaw, Catherine Leblanc, Dimitrios Lizos, Cathy Ritchie, Vikki Furminger, Sarah Lewis, Benoit Hornsperger, Nikolaus Johannes Stiefl, Sven Weiler
  • Patent number: D721488
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: January 27, 2015
    Inventor: Sarah Lewis